Phase 1 Clinical Trial: Carbapenem-resistant Enterbacterales (CRE)
$2,320,888N01FY2022AINIH
Dynport Vaccine Company, Llc, Frederick MD
Investigators
Abstract
The Phase I Clinical Trial Units provide a vehicle for the investigation of new therapeutic and immunomodulatory agents for the treatment of infectious disease.
View original record on NIH RePORTER →